Abbott Laboratories (NYSE:ABT) insider Daniel Gesua Sive Salvadori sold 71,157 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $55.00, for a total value of $3,913,635.00. Following the transaction, the insider now owns 144,955 shares in the company, valued at approximately $7,972,525. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel Gesua Sive Salvadori also recently made the following trade(s):

  • On Monday, October 23rd, Daniel Gesua Sive Salvadori sold 96,603 shares of Abbott Laboratories stock. The stock was sold at an average price of $56.21, for a total transaction of $5,430,054.63.
  • On Tuesday, September 26th, Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock. The stock was sold at an average price of $52.95, for a total transaction of $3,307,257.00.

Abbott Laboratories (ABT) traded up $0.71 during trading on Thursday, hitting $55.54. The company had a trading volume of 6,820,428 shares, compared to its average volume of 6,677,073. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The company has a market capitalization of $96,670.00, a PE ratio of 22.83, a price-to-earnings-growth ratio of 2.06 and a beta of 1.55. Abbott Laboratories has a fifty-two week low of $37.38 and a fifty-two week high of $56.69.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company’s revenue was up 28.8% on a year-over-year basis. During the same period last year, the company earned $0.59 earnings per share. equities analysts predict that Abbott Laboratories will post 2.5 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were given a $0.265 dividend. The ex-dividend date was Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a yield of 1.91%. Abbott Laboratories’s payout ratio is 87.60%.

TRADEMARK VIOLATION WARNING: “Daniel Gesua Sive Salvadori Sells 71,157 Shares of Abbott Laboratories (ABT) Stock” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/16/daniel-gesua-sive-salvadori-sells-71157-shares-of-abbott-laboratories-abt-stock.html.

Several equities research analysts have recently issued reports on the stock. Cowen and Company restated a “buy” rating and issued a $55.00 price objective on shares of Abbott Laboratories in a research note on Thursday, August 17th. Stifel Nicolaus restated a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 21st. BidaskClub downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a research report on Thursday, August 3rd. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $56.81.

A number of hedge funds have recently made changes to their positions in ABT. Tributary Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth about $106,000. Heritage Trust Co grew its position in shares of Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after buying an additional 200 shares during the period. Winfield Associates Inc. grew its position in shares of Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock worth $116,000 after buying an additional 89 shares during the period. Thompson Davis & CO. Inc. grew its position in shares of Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after buying an additional 370 shares during the period. Finally, V Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth about $127,000. Hedge funds and other institutional investors own 70.64% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.